Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosis factor receptor p75 in serum during highly active antiretroviral therapy of HIV type 1 disease - PubMed (original) (raw)
Clinical Trial
. 2000 Sep 1;16(13):1215-21.
doi: 10.1089/08892220050116989.
Affiliations
- PMID: 10957719
- DOI: 10.1089/08892220050116989
Clinical Trial
Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosis factor receptor p75 in serum during highly active antiretroviral therapy of HIV type 1 disease
M P Look et al. AIDS Res Hum Retroviruses. 2000.
Abstract
The chronic immune activation state in HIV disease leads to increased activity of the rate-limiting tryptophan-kynurenine pathway enzyme indoleamine 2,3-dioxygenase (2,3-IDO), thereby increasing the formation of neurotoxic tryptophan metabolites such as kynurenine and quinolinic acid. We investigated whether highly active antiretroviral therapy (HAART) (median duration, 100 days; range, 50-188 days) lowers serum levels of these metabolites in HIV-infected individuals and if so, whether this was paralleled by changes in a surrogate marker for immune activation, i.e., soluble tumor necrosis factor receptor p75 (sTNFR p75) concentrations. Baseline quinolinic acid (848 nM, 95% CI 567-1130 vs. 303 nM, 95% CI 267.1-339.5) and kynurenine (4.1 microM, 95% CI 3.3-4.9 vs. 2.7 microM, 95% CI 2.4-2.9) concentrations as well as the mean kynurenine-to-tryptophan ratio (108.2, 95% CI 76.1-140.4 vs. 51.4, 95% CI 47.6-55.3) in 17 HIV-1-infected outpatients (7 with AIDS) were significantly higher than those in 55 healthy age-matched controls (p < 0.01), respectively. Serum quinolinic acid concentrations in 14 of 17 patients decreased (mean, -44.4%) during HAART in comparison with baseline (471.2 nM, 95% CI 288-654.3; p = 0. 022). Thirteen of these 14 patients also had decreases in sTNFR p75 concentrations. Overall, the mean sTNFR p75 concentration decreased by 36.3% (13.5 ng/ml, 95% CI 9.3-17.8 vs. 8.6 ng/ml, 95% CI 5.9-11. 4; p = 0.01, n = 17). Reduction in viral load through HAART and subsequent mitigation of the pathological immune activation state in HIV disease may have reduced 2,3-IDO over activation. This eventually led to a decrease in quinolinic acid formation. The parallel reduction of the immune activation marker sTNFR p75 supports this hypothesis.
Similar articles
- The kynurenine pathway activities in a sub-Saharan HIV/AIDS population.
Bipath P, Levay PF, Viljoen M. Bipath P, et al. BMC Infect Dis. 2015 Aug 19;15:346. doi: 10.1186/s12879-015-1087-5. BMC Infect Dis. 2015. PMID: 26285873 Free PMC article. - Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.
Schefold JC, Zeden JP, Fotopoulou C, von Haehling S, Pschowski R, Hasper D, Volk HD, Schuett C, Reinke P. Schefold JC, et al. Nephrol Dial Transplant. 2009 Jun;24(6):1901-8. doi: 10.1093/ndt/gfn739. Epub 2009 Jan 20. Nephrol Dial Transplant. 2009. PMID: 19155537 - Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviral therapy.
Look MP, Riezler R, Berthold HK, Stabler SP, Schliefer K, Allen RH, Sauerbruch T, Rockstroh JK. Look MP, et al. Metabolism. 2001 Nov;50(11):1275-81. doi: 10.1053/meta.2001.27201. Metabolism. 2001. PMID: 11699044 Clinical Trial. - The kynurenine pathway and quinolinic acid: pivotal roles in HIV associated neurocognitive disorders.
Kandanearatchi A, Brew BJ. Kandanearatchi A, et al. FEBS J. 2012 Apr;279(8):1366-74. doi: 10.1111/j.1742-4658.2012.08500.x. Epub 2012 Mar 27. FEBS J. 2012. PMID: 22260426 Review. - Oxidative and Nitrosative Stress as Well as the Tryptophan Catabolites Pathway in Depressive Disorders.
Wigner P, Czarny P, Galecki P, Sliwinski T. Wigner P, et al. Psychiatr Danub. 2017 Dec;29(4):394-400. doi: 10.24869/psyd.2017.394. Psychiatr Danub. 2017. PMID: 29197195 Review.
Cited by
- Kynurenine pathway metabolites in humans: disease and healthy States.
Chen Y, Guillemin GJ. Chen Y, et al. Int J Tryptophan Res. 2009;2:1-19. doi: 10.4137/ijtr.s2097. Epub 2009 Jan 8. Int J Tryptophan Res. 2009. PMID: 22084578 Free PMC article. - Theiler's virus infection: a model for multiple sclerosis.
Oleszak EL, Chang JR, Friedman H, Katsetos CD, Platsoucas CD. Oleszak EL, et al. Clin Microbiol Rev. 2004 Jan;17(1):174-207. doi: 10.1128/CMR.17.1.174-207.2004. Clin Microbiol Rev. 2004. PMID: 14726460 Free PMC article. Review. - Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques.
Boasso A, Vaccari M, Fuchs D, Hardy AW, Tsai WP, Tryniszewska E, Shearer GM, Franchini G. Boasso A, et al. J Immunol. 2009 Apr 1;182(7):4313-20. doi: 10.4049/jimmunol.0803314. J Immunol. 2009. PMID: 19299731 Free PMC article. - Tryptophan depletion in context of the inflammatory and general nutritional status of a low-income South African HIV-infected population.
Bipath P, Levay PF, Viljoen M. Bipath P, et al. J Health Popul Nutr. 2016 Feb 17;35:5. doi: 10.1186/s41043-016-0042-4. J Health Popul Nutr. 2016. PMID: 26887418 Free PMC article. - Involvement of quinolinic acid in AIDS dementia complex.
Guillemin GJ, Kerr SJ, Brew BJ. Guillemin GJ, et al. Neurotox Res. 2005;7(1-2):103-23. doi: 10.1007/BF03033781. Neurotox Res. 2005. PMID: 15639803 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials